RESEARCH-USE BIOSIMILAR ANTIBODY
Brentuximab
Antibody-drug conjugate · IgG1
Brentuximab (CAC-10) is a chimeric antibody targeting CD30. Brentuximab is conjugated with Monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107A). Brentuximab can be used for the research of cancer, such as lymphoma.
TARGETTNFRSF8
YAntibody-drug conjugate
CATALOGSC-BS-703
CATALOG NUMBERSC-BS-703
MOLECULAR WEIGHTApprox. 145.48 kDa
PRODUCT FORMATAntibody-drug conjugate
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Brentuximab (CAC-10) is a chimeric antibody targeting CD30. Brentuximab is conjugated with Monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107A). Brentuximab can be used for the research of cancer, such as lymphoma.
Brentuximab is a recombinant research-use antibody directed against TNFRSF8.